Traders should monitor for upcoming FDA feedback and potential breakthrough device designation confirmation. Positive developments could re-rate the stock given the company's small market cap ($13M) and high leverage to regulatory progress.
Price Chart
Executive Summary
BioCardia announced that the FDA has accepted its pre-submission package for the Helix Transendocardial Delivery Catheter, a key delivery system for cardiac cell, gene, and protein therapeutics. The FDA's acceptance and ongoing consultations with CDRH and CBER may accelerate the approval pathway for both the device and the company's CardiAMP Cell Therapy for ischemic heart failure.
Key Facts
- FDA accepted pre-submission package for Helix Transendocardial Delivery Catheter.
- CDRH to lead review in consultation with CBER; CBER's CardiAMP Breakthrough Designation acknowledged.
- Helix enables minimally invasive, targeted intramyocardial delivery of therapeutics with superior retention.
- Potential catalyst for broader approval of cardiac cell and gene therapies, including CardiAMP for ischemic HFrEF.
- Upcoming regulatory milestones in Q1 and Q2 2026 with PMDA in Japan and Euro PCR presentation.
Financial Impact
Non-dilutive regulatory catalyst with potential to unlock value in BioCardia's platform; no immediate revenue impact but enhances commercial viability of future therapies.
Risk Factors
- Regulatory delays or rejection of the Helix catheter despite pre-submission acceptance.
- Company's liquidity risk and need for additional funding, as highlighted in forward-looking statements.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3256943 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 8d ago | 8-K | $0.8975 $1.04 | ▲ +15.88% | ▲ +15.54% | $0.9033 (+0.65%) |
Oct 19, 2026 8d ago | Press Release | $0.9000 $1.04 | ▲ +15.56% | ▲ +15.22% | $0.9033 (+0.37%) |
Oct 7, 2026 20d ago | 8-K | $1.09 $1.06 | ▼ −2.75% | ▼ −2.33% | $0.9033 (−17.13%) |
Oct 1, 2026 26d ago | 8-K | $1.02 $1.04 | ▲ +1.96% | ▲ +1.22% | $0.9033 (−11.44%) |
Oct 1, 2026 26d ago | Press Release | $1.02 $1.04 | ▲ +1.96% | ▲ +1.22% | $0.9033 (−11.44%) |
Sep 23, 2026 4w ago | 8-K | $1.05 $1.07 | ▲ +1.90% | ▲ +1.99% | $0.9033 (−13.97%) |
Sep 23, 2026 4w ago | Press Release | $1.05 $1.07 | ▲ +1.90% | ▲ +1.99% | $0.9033 (−13.97%) |
Sep 10, 2026 6w ago | 8-K | $1.10 $1.08 | ▼ −1.82% | ▼ −2.67% | $0.9033 (−17.88%) |
Aug 24, 2026 9w ago | 8-K | $1.06 $1.13 | ▲ +6.60% | ▲ +6.28% | $0.9033 (−14.78%) |
Aug 5, 2026 11w ago | Press Release | $0.9500 $0.9496 | ▼ −0.04% | ▲ +0.12% | $0.9033 (−4.92%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers